Compound ID | 1353
Class: Drug combination: beta-lactam + beta-lactamase inhibitor
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Combination treatment. |
| Institute where first reported: | Novartis |
| Highest development stage: | Preclinical |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/140855264 |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/43672 |
| Citation: | https://academic.oup.com/jac/article-abstract/75/6/1530/5766087?redirectedFrom=fulltext |